Switch theme
Sign up to access all valuation multiples
LBX Pharmacy Chain JSC is a China-based company engages in the sale of medicine and health products. The company is engaged in retailing drugs and other related products, including Chinese and Western medicine, prepared slices of Chinese crude drugs, health equipment, healthy food, and personal care products and life care products. The company is also involved in the wholesale and manufacture of drugs.
2005
n/a
LTM Revenue $3.3B
LTM EBITDA $308M
$2.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
LBX Pharmacy has a last 12-month revenue of $3.3B and a last 12-month EBITDA of $308M.
In the most recent fiscal year, LBX Pharmacy achieved revenue of $3.1B and an EBITDA of $403M.
LBX Pharmacy expects next 12-month revenue of XXX and NTM EBITDA of XXX
See LBX Pharmacy valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $3.1B | $3.2B | XXX | XXX | XXX |
| Gross Profit | $695M | $886M | XXX | XXX | XXX |
| Gross Margin | 22% | 28% | XXX | XXX | XXX |
| EBITDA | $403M | $295M | XXX | XXX | XXX |
| EBITDA Margin | 13% | 9% | XXX | XXX | XXX |
| Net Profit | $92.2M | $108M | XXX | XXX | XXX |
| Net Margin | 3% | 3% | XXX | XXX | XXX |
| Net Debt | $149M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, LBX Pharmacy's stock price is CNY 19 (or $3).
LBX Pharmacy has current market cap of CNY 14.3B (or $2.0B), and EV of CNY 18.3B (or $2.5B).
See LBX Pharmacy trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5B | $2.0B | XXX | XXX | XXX | XXX | $0.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, LBX Pharmacy has market cap of $2.0B and EV of $2.5B.
LBX Pharmacy's trades at 0.8x LTM EV/Revenue multiple, and 8.2x LTM EBITDA.
Analysts estimate LBX Pharmacy's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for LBX Pharmacy and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.5B | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 8.5x | XXX | XXX | XXX |
| P/E | 17.7x | XXX | XXX | XXX |
| P/E/Growth | 0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLBX Pharmacy's NTM/LTM revenue growth is 13%
LBX Pharmacy's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, LBX Pharmacy's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate LBX Pharmacy's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for LBX Pharmacy and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -27% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 22% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 26% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Oriola | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
LBX Pharmacy acquired XXX companies to date.
Last acquisition by LBX Pharmacy was XXXXXXXX, XXXXX XXXXX XXXXXX . LBX Pharmacy acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was LBX Pharmacy founded? | LBX Pharmacy was founded in 2005. |
| Where is LBX Pharmacy headquartered? | LBX Pharmacy is headquartered in China. |
| Is LBX Pharmacy publicy listed? | Yes, LBX Pharmacy is a public company listed on SHG. |
| What is the stock symbol of LBX Pharmacy? | LBX Pharmacy trades under 603883 ticker. |
| When did LBX Pharmacy go public? | LBX Pharmacy went public in 2015. |
| Who are competitors of LBX Pharmacy? | Similar companies to LBX Pharmacy include e.g. MedPlus India, Pague Menos, Droga Raia, Redcare Pharmacy. |
| What is the current market cap of LBX Pharmacy? | LBX Pharmacy's current market cap is $2.0B |
| What is the current revenue of LBX Pharmacy? | LBX Pharmacy's last 12-month revenue is $3.3B. |
| What is the current EBITDA of LBX Pharmacy? | LBX Pharmacy's last 12-month EBITDA is $308M. |
| What is the current EV/Revenue multiple of LBX Pharmacy? | Current revenue multiple of LBX Pharmacy is 0.8x. |
| What is the current EV/EBITDA multiple of LBX Pharmacy? | Current EBITDA multiple of LBX Pharmacy is 8.2x. |
| What is the current revenue growth of LBX Pharmacy? | LBX Pharmacy revenue growth between 2023 and 2024 was 3%. |
| Is LBX Pharmacy profitable? | Yes, LBX Pharmacy is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
